Acrus BioMed, a resident company of the Technopolis Moscow Special Economic Zone (SEZ), became Russia’s first company in Russia to produce samples of high-tech cell therapies for clinical trials.

Binnopharm Group, a prominent Russian pharmaceutical company, has become a participant in the business mission of the Russian Export Center (REC) in Indonesia under the national brand “Made in Russia” ...

Patients from 45 Russian regions will soon the domestic drug Seniprutug for the treatment of ankylosing spondylitis, TASS reports. Its development was carried out by the Russian company Biocad ...

The Federal Medical and Biological Agency (FMBA) of Russia has announced that the submission of documents for registration of its vaccines for the prevention of pneumococcal and meningococcal ...

Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), said that phase II of clinical trials of the Russian vaccine against allergy to birch pollen and similar allergens (apple ...

The Russian biopharmaceutical company PSK Pharma has received a registration certificate for the first Russian-made drug with the active ingredient etanercept under the trade name Rivia. It is a ...

Russian and foreign molecular biologists have proposed a new approach to the study of G-protein-coupled receptors, an important class of signal receptors. As the Center for Scientific Communication at ...

The Ministry of Industry and Trade of the Russian Federation has begun accepting applications for the Start-Medizdelia (Medical Products) competition, the winners of which will receive grants of up to ...

Binnopharm Group, one of Russia’s leading pharmaceutical companies, and the Research Institute of Clinical and Experimental Lymphology (NIIKEL), a branch of the Instutute of Cytology and Genetics of ...

Pharmaceutical enterprises of the Technopolis Moscow Special Economic Zone (SEZ) introduced 37 new drugs to the market in 2024, including drugs for the treatment of cancer, multiple sclerosis, chronic ...

The Russian company Pharmasyntez is preparing to register and launch Vamotinib (vamotinib), which is in phase III clinical trials. The drug was fully developed and manufactured in Russia, according to ...

Innovative targeted drugs have transformed the treatment paradigm, addressing the underlying causes of diseases previously deemed incurable rather than merely alleviating symptoms. The adoption of ...